Helus Pharma reports positive Phase 3 results for HLP003 and appoints new CEO

Helus Pharma announced that its Phase 3 APPROACH trial of HLP003 met its primary endpoint, showing a 7.6‑point placebo‑adjusted improvement on the MADRAS scale. The study enrolled 222 adults and demonstrated rapid onset of effect. The company also named Michael Halstead as chief executive officer. Helus expects topline data from the trial in Q4 2026.

The positive trial data could open a new revenue stream for Helus Pharma, as the company plans to commercialize HLP003 for major depressive disorder (the company expects topline data in Q4 2026). Jefferies analysts said the efficacy exceeded investor expectations, which may support the recent >20% pre‑market share jump.

  • 1Helus Pharma completed enrollment of 222 adults in the Phase 3 APPROACH trial.
  • 2The trial met its primary endpoint with a 7.6‑point placebo‑adjusted improvement on the MADRAS scale.
  • 3Net loss for Q2 FY2027 was $103.1 million, versus $33.7 million a year earlier.
  • 4Cash on hand at September 30 2026 was $171.1 million.
  • 5Operating expenses excluding share‑based compensation for the quarter were $39.6 million.
  • 6Michael Halstead was appointed chief executive officer.

Sources